Year |
Citation |
Score |
2022 |
Revenko A, Carnevalli LS, Sinclair C, Johnson B, Peter A, Taylor M, Hettrick L, Chapman M, Klein S, Solanki A, Gattis D, Watt A, Hughes AM, Magiera L, Kar G, ... ... Mele DA, et al. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. Journal For Immunotherapy of Cancer. 10. PMID 35387780 DOI: 10.1136/jitc-2021-003892 |
0.324 |
|
2020 |
Borodovsky A, Barbon CM, Wang Y, Ye M, Prickett L, Chandra D, Shaw J, Deng N, Sachsenmeier K, Clarke JD, Linghu B, Brown GA, Brown J, Congreve M, Cheng RK, ... ... Mele DA, et al. Small molecule AZD4635 inhibitor of AR signaling rescues immune cell function including CD103 dendritic cells enhancing anti-tumor immunity. Journal For Immunotherapy of Cancer. 8. PMID 32727810 DOI: 10.1136/Jitc-2019-000417 |
0.382 |
|
2020 |
Chandra D, Barbon CM, Borodovsky A, Wang Y, Ye M, Prickett L, Sachsenmeier K, Shao W, Barrett C, Fawell S, Mele DA, Schuller A. Abstract A87: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+ dendritic cells Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-A87 |
0.43 |
|
2020 |
Grimster N, Drew L, Fawell S, Mele DA, Bommakanti G, Shen M, Xu K, Song K, Ziegler R, Kettle J, Mfuh A, Sheilds J. Abstract A56: Releasing the brake on T-cell activation through inhibition of HPK1 Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-A56 |
0.509 |
|
2019 |
O' Donovan DH, Mao Y, Mele DA. The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Current Medicinal Chemistry. PMID 31250749 DOI: 10.2174/0929867326666190620103105 |
0.327 |
|
2019 |
Barbon CM, Borodovsky A, Wang Y, Prickett L, Sachsenmeier K, Schuller A, Shao W, Barrett C, Fawell S, Mele DA. Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-192 |
0.439 |
|
2018 |
Langdon S, Hughes A, Taylor MA, Kuczynski EA, Mele DA, Delpuech O, Jarvis L, Staniszewska A, Cosulich S, Carnevalli LS, Sinclair C. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology. 7: e1458810. PMID 30221055 DOI: 10.1080/2162402X.2018.1458810 |
0.359 |
|
2016 |
Ghosh S, Taylor A, Chin M, Huang HR, Conery AR, Mertz JA, Salmeron A, Dakle PJ, Mele D, Cote A, Jayaram H, Setser JW, Poy F, Hatzivassiliou G, DeAlmeida-Nagata D, et al. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. The Journal of Biological Chemistry. PMID 27056325 DOI: 10.1074/Jbc.M115.708560 |
0.399 |
|
2013 |
Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM, Lora JM. BET bromodomain inhibition suppresses TH17-mediated pathology. The Journal of Experimental Medicine. 210: 2181-90. PMID 24101376 DOI: 10.1084/Jem.20130376 |
0.414 |
|
2011 |
Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America. 108: 16669-74. PMID 21949397 DOI: 10.1073/Pnas.1108190108 |
0.408 |
|
2011 |
Mele DA, Sampson JF, Huber BT. Th17 differentiation is the default program for DPP2-deficient T-cell differentiation. European Journal of Immunology. 41: 1583-93. PMID 21469121 DOI: 10.1002/Eji.201041157 |
0.552 |
|
2009 |
Danilova OV, Tai AK, Mele DA, Beinborn M, Leiter AB, Greenberg AS, Perfield JW, Defuria J, Singru PS, Lechan RM, Huber BT. Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity. Endocrinology. 150: 5240-8. PMID 19819973 DOI: 10.1210/En.2009-0386 |
0.458 |
|
2009 |
Mele DA, Bista P, Baez DV, Huber BT. Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescence. Cell Cycle (Georgetown, Tex.). 8: 2425-34. PMID 19556882 DOI: 10.4161/Cc.8.15.9144 |
0.525 |
|
2008 |
Bista P, Mele DA, Baez DV, Huber BT. Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1. Molecular Immunology. 45: 3618-23. PMID 18555530 DOI: 10.1016/J.Molimm.2008.05.001 |
0.547 |
|
Show low-probability matches. |